Killam Seminar Series: Acute Cerebroprotection in Ischemic Stroke
![](/neuro/files/neuro/styles/fullwidth_breakpoints_theme_moriarty_small_1x/public/channels/image/killamseminars-generic_channel_fb_post_1200x630_1.png?itok=944beIBC×tamp=1723484486)
Grâce à la générosité des fiducies Killam, Le Neuro convoque lors d’une série de séminaires des conférenciers d’exception dont les travaux passionnent ses chercheurs et ceux de l’Université Æ»¹ûÒùÔº.Ìý
Pour assister en personne,Ìý
Pour regarder via Vimeo,Ìý
Johannes Boltze
Professeur de neurosciences, Université de Warwick, Royaume-Uni
±áô³Ù±ð:Ìýedith.hamel [at] mcgill.ca (Edith Hamel)
Abstract:ÌýIschemic stroke (IS) is caused by a sudden occlusion of a brain-supplying artery. Stroke is frequent due to the wide representation of its risk factors, a leading cause of death and the most frequent reason for permanent disability in adulthood. Despite its immense medical and socio-economic impact, re-establishing cerebral blood flow by recanalizing the occluded vessel is the only established therapeutic option. However, recanalization therapies are limited by narrow time therapeutic windows, the requirement of specific infrastructure, and numerous contraindications. Cerebroprotective therapies shielding neurons and glia from ischemic damage would be beneficial in IS. Previous research on such approaches has been futile for decades but recent preclinical and clinical developments have caused a renaissance of cerebroprotective paradigms. The talk will briefly introduce the complex pathophysiology of IS and explain difficulties the field faced during the development of cerebroprotective paradigms in the past. It will then introduce the novel key strategy of acute cerebroprotection and will explain why chances for a therapeutic breakthrough are now higher than ever. The main part of the talk will provide detailed insights into selected, currently investigated cerebroprotective approaches for IS by providing data from basic science and translational animal experiments. The talk will conclude by providing a brief overview of the recently established translational research concept of multicenter preclinical trials.